# Influx Healthtech share price today (Influx Healthtech Ltd, NSE: INFLUX)

> Influx Healthtech share price today: ₹268.50 at the NSE close on 3 November 2026, up 43.6% in a year. Influx Healthtech (NSE: INFLUX) is worth ₹622 crore, trades at a P/E of 32.5 and has closed between ₹179.70 and ₹312.35 over the past 52 weeks. > Influx Healthtech Ltd's results are improving, and its P/E is near the top of its own history, higher than 83% of past readings. INFLUX · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/influx-healthtech-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹268.50 (+43.6% in a year)
- P/E: 32.5× (higher than 83% of the last 1 year)
- Revenue (Mar 2026): ₹80.0 Cr (+40.4% on a year ago)
- Profit (Mar 2026): ₹11.0 Cr (+37.5% on a year ago)
- Operating margin: 19.0% (−1.0 points on a year ago)
- ROCE: 38%, FY26

The main question: profits are rising, but only 44% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Influx Healthtech share price today? Influx Healthtech Ltd's share price was ₹268.50 at the close on 3 November 2026. It has been rising for 69 weeks. That is 5.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹180 and ₹312, and at that close it sat 67% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 1 week in a row. Over the last 1 year the share price moved +100% while the NIFTY 500 moved −7%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Influx Healthtech this quarter? One change stood out: number of shareholders up 27% in a year. 1. Number of shareholders up 27% in a year 1,296 shareholders in the September 2026 quarter, against 1,022 a year earlier. ## What are Influx Healthtech's latest quarterly results? For January to March 2026 (the quarter ended 31 March 2026), Influx Healthtech reported revenue of ₹80.0 crore, up 40.4% from ₹57.0 crore a year earlier, and a profit of ₹11.0 crore, up 37.5% from ₹8.00 crore. ### Influx Healthtech results: January to March 2026 against a year earlier

| Measure | January to March 2026 | January to March 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹80.0 crore | ₹57.0 crore | +40.4% |
| Profit | ₹11.0 crore | ₹8.00 crore | +37.5% |
| Earnings per share | ₹4.56 | ₹4.21 | +8.3% |
| Operating margin | 19.0% | 20.0% | −1.0 points |

The next results, for April to June 2026, were due by 14 August 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). This page shows them once our weekly data update has read them. Influx Healthtech's management discussed these results on a call held on 22 May 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 31 March 2026). Revenue and profit in ₹ crore.)

## What is the Influx Healthtech share price history? Influx Healthtech closed at ₹268.50 on 3 November 2026, up 43.6% from ₹186.95 a year earlier (31 October 2025). Its highest weekly close since June 2025 was ₹302.75 on 28 August 2026. ### Influx Healthtech share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹257.00 | +4.5% |
| 1 month ago · 1 Oct 2026 | ₹256.00 | +4.9% |
| 6 months ago · 30 Apr 2026 | ₹268.90 | −0.1% |
| 1 year ago · 31 Oct 2025 | ₹186.95 | +43.6% |
| Earliest weekly close in our records · 27 Jun 2025 | ₹134.45 | +99.7% |
| Highest weekly close since June 2025 · 28 Aug 2026 | ₹302.75 | −11.3% |
| Lowest weekly close since June 2025 · 4 Jul 2025 | ₹131.35 | +104.4% |
| 52-week high (weekly close) · 6 Jul 2026 | ₹312.35 | −14.0% |
| 52-week low (weekly close) · 11 Nov 2025 | ₹179.70 | +49.4% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (78 weekly closes from 27 June 2025 to 3 November 2026.)

## What is the latest news on Influx Healthtech? 3 Nov 2026: Influx Healthtech closed at ₹268.50, up 4.5% on the week and up 4.9% on the month. 22 May 2026: Influx Healthtech held its results call for January to March 2026. Management guided: FY27 revenue growth minimum 25-30% (prepared, conservative estimate, directional)

### Earlier

- Results for January to March 2026: Revenue up 40.4% and profit up 37.5% on a year earlier. ## What dividend does Influx Healthtech pay? Influx Healthtech has paid no dividend on the NSE since its first NSE close in our records (27 June 2025), the start of the period we checked. No. Influx Healthtech Ltd paid out 0% of its profit as dividends in each of its last 5 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Influx Healthtech management say on the latest results call? On the call for January to March 2026, held on 22 May 2026, Influx Healthtech's management guided: FY27 revenue growth minimum 25-30% (prepared, conservative estimate, directional)

> “When we start, we will be commissioning 2.5x of our current capacity, which can take us to 450-500 crores in a couple of years. This is our expectation. We will still have space if required. It is a dynamic industry, so if a new technology emerges, we have the space to react.”
> Dr. Munir Chandniwala, on the call for January to March 2026

### What management guided

- New facility commissioning July-August 2026 with regulatory licensing process starting immediately (prepared, specific dates); Olahe Wellness similarly expected August 2026 licensing approval (prepared, specific)
- New facility FY27 revenue contribution ₹40-50 crores contingent on demand absorption (extracted, range); ₹450-500 crores FY29 goal (prepared, specific, multi-year)
- Operating margin FY27 20-22% (extracted, specific range) with profit margin 14-15% (prepared, specific); represents flat-to-accretive trajectory versus FY26's 20.3% operating profit and 14.0% profit despite higher revenue growth. - Pet care capacity 25 tons/month within 2-3 months from current 16-18 tons (prepared, specific); export growth 10-15% annually with plus 5-7% on a year earlier incremental pursuit (prepared, directional)

Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/58332-22-May-2026.pdf). (From the call for January to March 2026, 22 May 2026.)

## What to watch in Influx Healthtech's next results? When Influx Healthtech reports April to June 2026, these are the 4 checks that show whether the story is still on course. First: New facility commissioning and regulatory licensing approval pace for July-August 2026 - critical credibility checkpoint validating ₹450-500 crore FY29 goal and growth algorithm sustainability. - What to check (from the call)
- New facility commissioning and regulatory licensing approval pace for July-August 2026 - critical credibility checkpoint validating ₹450-500 crore FY29 goal and growth algorithm sustainability. - Gross margin recovery trajectory in April to June 2026 earnings print - validates cost-plus pass-through lag normalization hypothesis and signals whether client mix strategy remains sustainable without repricing adjustments. - Tanzania product registration approvals for 14-15 SKUs - indicators of export revenue expansion pathway viability and timeline to 10-20% export contribution within multi-year window. - Olahe Wellness capital spending burn rate and RTD beverage market launch execution - validates retort technology differentiation strategy and liquid plant-based protein viability in competitive functional beverage category. ## Which stock lists is Influx Healthtech on? Influx Healthtech is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 617.2060491493384](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Influx Healthtech profitable? Influx Healthtech Ltd earned ₹11.0 Cr of net profit in the Mar 2026 quarter, +37.5% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY26 profit was ₹21.0 Cr. That is 13.8% of the quarter's revenue. For the full year, FY26 profit was ₹21.0 Cr (+61.5% on the year before). ## How much revenue does Influx Healthtech make, and is it growing? Influx Healthtech Ltd reported ₹80.0 Cr of revenue in the Mar 2026 quarter, +40.4% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. The last full year, FY26, came in at ₹147 Cr. A growth rate over several years is not shown, because there are too few years of figures to work one out properly. FY26 revenue was ₹147 Cr, +40.0% on the year before. ## How much of every ₹100 of sales does Influx Healthtech keep? Influx Healthtech Ltd's operating margin was 19.0% in the Mar 2026 quarter, 1.0 percentage points lower than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between 11.0% and 20.0%. The latest quarter is within that range. Why: the operating margin move is clear, but the cost details behind it are not in our data, so we show the move without guessing the reason. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is Influx Healthtech's profit turning into cash? Over the last 3 years, 44% of Influx Healthtech Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹4.0 Cr of operating cash against ₹21.0 Cr of profit. After ₹16.0 Cr of spending on assets, free cash was −₹12.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 44% of profit came in as cash: the cash cycle got 74 days longer between FY22 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 74 days longer. The next section looks at where the cash is stuck. ## Where does Influx Healthtech's cash go? Influx Healthtech Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 64 days in FY26, up from −10 days in FY22. It spent ₹34.0 Cr on assets over the last 3 years. Customers take 84 days to pay, and stock sits for 98 days on average. At FY26 sales of ₹147 Cr, each day of that cycle ties up about ₹0.4 Cr, so roughly ₹26.0 Cr is tied up in the business at any time. FY26: customers took 84 days to pay and stock sat for 98 days, about 3.2 months of sales sitting as stock, for a full cycle of 64 days, longer than FY22's −10. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 98 days. Customers pay about 84 days after that. Suppliers are paid at 118 days. Together that makes the 64-day cycle. Spending on assets: ₹34.0 Cr over the last 3 years, against ₹9.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹3.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Influx Healthtech's P/E ratio, and how does it compare with its own history? Influx Healthtech Ltd's P/E is 32.5×, near the high end of its own history: higher than 83% of past readings. Its usual P/E (the middle reading) is 26.8×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +21.3% while the price moved +43.6%. The price did better than earnings, which pushed the multiple up within its own range. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 50% on reported income across 3 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Influx Healthtech business getting better or worse? Influx Healthtech Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Influx Healthtech earn on its capital? Influx Healthtech Ltd earned a ROCE of 38% in FY26. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a 14.3% net margin and 1.19× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 14.3% net margin × 1.19× asset turnover × 1.23× leverage (assets divided by equity) ≈ 20.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 50% on reported income across 3 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Influx Healthtech have too much debt? Influx Healthtech Ltd had ₹0.0 Cr of borrowings against ₹101 Cr of equity in FY26, so its debt is 0.00× its equity. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Over the last 3 of those years it spent ₹34.0 Cr on assets. The spending on assets is being paid for from cash, not new debt. ## What is the Influx Healthtech shareholding pattern? No group of Influx Healthtech Ltd's owners changed its stake by a full percentage point over the last 4 quarters. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. ## How far is Influx Healthtech from balance-sheet trouble? For Influx Healthtech Ltd, the Z-score is left out, because it comes from the second data source we could not check, and a safety score is not worth showing when two sources disagree. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Influx Healthtech rank in its industry? 49.7 out of 100, rank 41 of 44 in Pharma - Formulators, with 42% of the evidence available. It is provisional, so it is ranked below companies with full evidence. Influx Healthtech Ltd scores 49.7 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 41. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 16.2 + 17.9 + 10.2 + 5.4 = 49.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Influx Healthtech compared with? Influx Healthtech ranks 41 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 49.7 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. [Bharat Parenterals Ltd](https://www.sectoralpha.in/stocks/bharat-parenterals-ltd) BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative
28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. Influx Healthtech Ltd this page INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.2/35 · Revenue n/a · Profit n/a · Operating margin change -1 points · 15% evidence Capital efficiency 17.9/25 · ROCE 38.4% · Operating margin 19% · 57% evidence Valuation 10.2/20 · P/E 32× · PEG n/a · 15% evidence Relative strength 5.4/20 · Lead over its industry -10.3% · Lead over NIFTY 500 11.6% · 1 year 41.5% · 100% evidence · 5 of 12 weeks ahead Exact sum: 16.2 + 17.9 + 10.2 + 5.4 = 49.7 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Influx Healthtech in size? Influx Healthtech is the 43rd largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Bafna Pharmaceuticals, Bajaj Healthcare, Lincoln Pharmaceuticals, Zim Laboratories and Kilitch Drugs (India). Just below it: Syncom Healthcare. ### Pharma - Formulators companies close in size

1. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) ₹1,060 crore
2. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) ₹1,031 crore
3. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) ₹1,000 crore
4. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ₹731 crore
5. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) ₹704 crore
6. Influx Healthtech Ltd ₹612 crore
7. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) ₹17 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Rama Steel Tubes Ltd](https://www.sectoralpha.in/stocks/rama-steel-tubes-ltd) ₹614 crore · Steel - Tubes/Pipes
2. [India Power Corporation Ltd](https://www.sectoralpha.in/stocks/india-power-corporation-ltd) ₹612 crore · Power - Generation/Distribution
3. Influx Healthtech Ltd ₹612 crore
4. [Coffee Day Enterprises Ltd](https://www.sectoralpha.in/stocks/coffee-day-enterprises-ltd) ₹611 crore · Quick Service Restaurant - QSR
5. [Hardwyn India Ltd](https://www.sectoralpha.in/stocks/hardwyn-india-ltd) ₹610 crore · Trading

## What else do people ask about Influx Healthtech? ### What is Influx Healthtech's share price today? Influx Healthtech Ltd's share price is ₹268.50, +43.6% over the past year. The whole company is worth ₹622 Cr on the market. In the last 52 weeks it traded between ₹180 to ₹312; today it is 67% of the way up from the low, 5.6% above its 200-day average (as of 3 November 2026). ### What were Influx Healthtech's latest quarterly results? Influx Healthtech Ltd reported revenue of ₹80.0 Cr and net profit of ₹11.0 Cr for the Mar 2026 quarter. Revenue rose 40.4% and profit rose 37.5% compared with a year earlier. Earnings per share were ₹4.56. The operating margin was 19.0%, 1.0 percentage points lower than a year earlier (as of 3 November 2026). ### What is Influx Healthtech's market cap? Influx Healthtech Ltd's market capitalisation is ₹622 Cr at a share price of ₹268.50. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Influx Healthtech performing? Influx Healthtech Ltd's share price has been rising for 69 weeks. In its latest quarter, revenue rose 40.4% and profit rose 37.5% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 1 week running (as of 3 November 2026). ### Will Influx Healthtech's share price go up? This page does not forecast Influx Healthtech Ltd's share price. What it shows instead: the share price is ₹268.50, and it has been rising for 69 weeks. Its P/E of 32.5× is higher than 83% of its own last 1 years (as of 3 November 2026). ### Who owns Influx Healthtech? Promoters own 73.5% of Influx Healthtech Ltd, foreign institutions 0.4%, domestic institutions 7.3% and the public 18.7% (latest quarter). No group of owners changed its stake by a full point over the last two years (as of 3 November 2026). ### Where is Influx Healthtech in its business cycle? Influx Healthtech Ltd's FY26 operating margin was 20.0%, against a 5-year range of 11.0% to 20.0%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 19.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Influx Healthtech story? The main question: profits are rising, but only 44% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Influx Healthtech a stock worth studying right now? What the numbers show: Influx Healthtech Ltd's results are improving, and its P/E is near the top of its own history, higher than 83% of past readings. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Influx Healthtech share price forecast for 2026? What management itself guided: FY27 revenue growth minimum 25-30% (prepared, conservative estimate, directional)

## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.